Leukemia and Lymphoma
Leukemia and lymphoma research concentrates on these hematologic malignancies, seeking improved therapies and patient outcomes. Recent developments involve targeted therapies and immunotherapies, offering new hope for treatment. Minimal residual disease monitoring helps assess treatment effectiveness. Additionally, CAR-T cell therapy exhibits promise in treating both leukemia and lymphoma. This field aims to enhance treatment precision and minimize side effects while advancing the understanding of disease mechanisms, ultimately improving the prognosis for individuals with these blood cancers.
- New therapies for leukemia and lymphoma.
- Minimal residual disease monitoring.
- CAR-T cell therapy in hematologic malignancies.
Related Conference of Leukemia and Lymphoma
Leukemia and Lymphoma Conference Speakers
Recommended Sessions
- Bleeding Disorders in Women
- Digital Health and Artificial Intelligence (AI) in Hematology
- Hematologic Gene Editing and Gene Therapies
- Hematology and Stem Cell Research
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Sickle Cell Disease
- Hemophilia Management and Research
- Hemostasis and Thrombosis
- Immunotherapy and Hematology
- Leukemia and Lymphoma
- Medicine in Hematology
- Molecular Hematology
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure
- Next-Generation Diagnostics and Imaging
- Novel Therapies for Blood Cancers
- Pediatric Hematology
- Platelet Disorders
- Sickle Cell Disease (SCD)
- Thalassemia Management
- Transfusion Medicine and Blood Banking